- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.09. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.08. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.08. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| APIMEDS PHARMACEUTICALS US Aktie jetzt für 0€ handeln | |||||
| 13.07. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.05. | Apimeds Pharmaceuticals US, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.05. | Apimeds settles disputes, stock to resume trading today | 3 | Investing.com | ||
| 04.05. | Apimeds Pharmaceuticals US, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 04.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.04. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Apimeds Pharmaceuticals US, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 25.03. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.03. | Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery | 203 | Business Wire | MATAWAN, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ("APUS" or the "Company") (NYSE... ► Artikel lesen | |
| 01.12.25 | Apimeds Pharmaceuticals US, Inc. and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE | 725 | Business Wire | Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-driven... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARIS LIFE SCIENCES | 26,600 | -0,75 % | Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance | Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole... ► Artikel lesen | |
| AKTIS ONCOLOGY | 21,940 | +2,38 % | Aktis Oncology Inc.: Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 | Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumorsEnrolling... ► Artikel lesen | |
| PARABILIS MEDICINES | 37,090 | +0,43 % | Parabilis auf Morgan-Stanley-Konferenz: Umfassende Strategie für Beta-Catenin-Plattform | ||
| QIAGEN | 38,410 | -0,74 % | Qiagen sorgt für Gesprächsstoff, Rheinmetall bleibt unter Druck, Nvidia zeigt sich freundlicher und Siemens Energy profitiert von neuer Zuversicht im KI-Segment | Die Zinserhöhung der Fed sowie die Aussicht auf weitere Zinsschritte in der nahen Zukunft scheinen die Märkte erstaunlich schnell verdaut zu haben. Statt weiterer Kursstürze gab es am Donnerstag dann... ► Artikel lesen | |
| DECOY THERAPEUTICS | 3,500 | +37,52 % | Decoy Therapeutics, Inc: Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding | Next-Generation D-MAVs Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility
... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 302,63 | +1,18 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,055 | +2,14 % | Tempus verlängert Datenpartnerschaft mit Recursion bis 2029 | ||
| MODERNA | 159,20 | +5,56 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| CG ONCOLOGY | 76,73 | -1,94 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,950 | +7,25 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,120 | +1,30 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock | ||
| MAZE THERAPEUTICS | 27,090 | +20,99 % | Maze Therapeutics auf Konferenz von H.C. Wainwright: Pipeline vor entscheidenden Tests | ||
| BIONTECH | 88,05 | +2,98 % | KAUFWELLE bei BioNTech: +3,4% - Ist das der Start der RALLYE? | ||
| VERA THERAPEUTICS | 36,040 | +5,23 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| ABSCI | 10,620 | +8,15 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test |
Das Unternehmen APIMEDS PHARMACEUTICALS US INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,730 Euro und damit -1,70 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APIMEDS PHARMACEUTICALS US INC finden Sie auf Wallstreet Online.